RDHL Redhill Biopharma Ltd.

6.87
+0.17  (+3%)
Previous Close 6.7
Open 6.74
Price To Book 6.13
Market Cap 194,892,900
Shares 28,368,690
Volume 22,363
Short Ratio
Av. Daily Volume 80,233

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 4Q 2019.
RHB-204
Nontuberculous mycobacteria (NTM) infections
Phase 2a enrolment to be completed 2H 2019.
YELIVA
Cholangiocarcinoma
Phase 1/2 poster presentation at EORTC-NCI-AACR November 16, 2018.
YELIVA
Refractory or relapsed multiple myeloma - cancer
Phase 3 data released July 30, 2018. Primary endpoint met but further trial required. FDA meeting planned for 2H 2019.
RHB-104 MAP US
Crohn’s disease
PDUFA date under priority review November 2, 2019.
RHB-105
H. pylori
Phase 3 top-line data released June 14, 2017 - primary endpoint met. Additional Phase 3 trial planned.
BEKINDA -GUARD
Gastroenteritis
Phase 2 top-line data released October 3, 2017 - primary endpoint met (borderline) - p=0.05. Follow up analysis identfied p value = 0.036. Phase 3 trial planned.
BEKINDA
IBS-D
Phase 2 initiated October 2016.
YELIVA
Hepatocellular carcinoma (HCC) - cancer

Latest News

  1. Israeli pharma could double its Triangle team before FDA approval this year
  2. RedHill Biopharma Reports Second Quarter 2019 Financial Results and Operational Highlights
  3. RedHill Biopharma Ltd. to Host Earnings Call
  4. 3 Small-Caps That Look Like Bargains at Current Trading Levels
  5. RedHill Biopharma to Host Second Quarter 2019 Financial Results Conference Call on July 23, 2019
  6. 3 Biotech Stocks That Could Double Your Money
  7. RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia®
  8. RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections
  9. She left one Triangle public company to become CSO of another local public pharma
  10. RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer
  11. RedHill Biopharma to Present at 2019 BIO International Convention
  12. RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch
  13. RedHill Biopharma Reports First Quarter 2019 Financial Results and Operational Highlights
  14. RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection
  15. Israeli firms ramps up in Raleigh as drug nears approval
  16. RedHill Biopharma to Host First Quarter 2019 Financial Results Conference Call on May 7, 2019
  17. RedHill Biopharma to Present at Three Conferences in April
  18. RedHill Biopharma to Present at the BIO-Europe Spring 2019 Conference
  19. RedHill Biopharma to Present at the 31st Annual ROTH Conference
  20. RedHill Biopharma Announces New European and Japanese Patents for Talicia®